Multicenter Retrospective Analysis of Nivolumab Monotherapy Outcomes in Advanced Renal Cell Carcinoma by the Spanish Genitourinary Oncology Group - Summary - MDSpire

Multicenter Retrospective Analysis of Nivolumab Monotherapy Outcomes in Advanced Renal Cell Carcinoma by the Spanish Genitourinary Oncology Group

  • By

  • Natalia Fernández-Díaz

  • María Mateos-González

  • Ana Pertejo-Fernández

  • Juan Diego Cacho-Lavín

  • María José Juan-Fita

  • Isabel Chirivella-González

  • Mikel Arruti-Ibarbia

  • Ovidio Fernández-Calvo

  • Natalia Fernández-Núñez

  • María José Méndez-Vidal

  • Martín Lázaro-Quintela

  • Aurea Molina-Díaz

  • Nieves Del Pozo-Alonso

  • Olatz Etxaniz-Ulazia

  • Silvia Margarita García-Acuña

  • Yoel Z. Betancor

  • Ainara Azueta-Etxebarria

  • Ana Calatrava-Fons

  • Helena Lombardía-Rodríguez

  • Lorena Alarcón-Molero

  • Leire Etxegarai-Ganboa

  • Abraham Antón-Cameselle

  • José Antonio Bello-Giz

  • Carlos Manuel Neira-De Paz

  • Teresa Cabaleiro

  • Teresa González-Serrano

  • José Antonio Ortiz-Rey

  • Felipe Sacristán-Lista

  • Silvia García-Rubín

  • Elisa Ortega

  • Cristina Carrato-Moñino

  • Santiago Aguín-Losada

  • Luis León-Mateos

  • Jorge García-González

  • Álvaro Pinto-Marín

  • Ignacio Duran

  • Rafael López-López

  • Urbano Anido-Herranz

  • Juan Ruiz-Bañobre

  • November 28, 2025

  • 0 min

Share

Objective:

To evaluate the efficacy of nivolumab in advanced renal cell carcinoma (aRCC) patients treated in routine clinical practice and assess the impact of pre-treatment factors on treatment outcomes.

Key Findings:
  • Median age of patients was 65 years; 27% were female and 73% male.
  • 90% of patients had an ECOG-PS score of 0 or 1.
  • Clear cell renal cell carcinoma was the predominant subtype (85%).
  • Nivolumab demonstrated a significant overall survival benefit in the real-world setting.
Interpretation:

The study confirms the efficacy of nivolumab in aRCC patients in routine clinical practice, aligning with findings from controlled clinical trials.

Limitations:
  • Retrospective design may introduce selection bias.
  • Limited generalizability due to the specific patient population and treatment settings.
Conclusion:

Nivolumab is effective in advanced renal cell carcinoma patients treated in routine clinical practice, with outcomes consistent with clinical trial data.

Original Source(s)

Multicenter Retrospective Analysis of Nivolumab Monotherapy Outcomes in Advanced Renal Cell Carcinoma by the Spanish Genitourinary Oncology Group

  • by Natalia Fernández-Díaz, María Mateos-González, Ana Pertejo-Fernández, Juan Diego Cacho-Lavín, María José Juan-Fita, Isabel Chirivella-González, Mikel Arruti-Ibarbia, Ovidio Fernández-Calvo, Natalia Fernández-Núñez, María José Méndez-Vidal, Martín Lázaro-Quintela, Aurea Molina-Díaz, Nieves Del Pozo-Alonso, Olatz Etxaniz-Ulazia, Silvia Margarita García-Acuña, Yoel Z. Betancor, Ainara Azueta-Etxebarria, Ana Calatrava-Fons, Helena Lombardía-Rodríguez, Lorena Alarcón-Molero, Leire Etxegarai-Ganboa, Abraham Antón-Cameselle, José Antonio Bello-Giz, Carlos Manuel Neira-De Paz, Teresa Cabaleiro, Teresa González-Serrano, José Antonio Ortiz-Rey, Felipe Sacristán-Lista, Silvia García-Rubín, Elisa Ortega, Cristina Carrato-Moñino, Santiago Aguín-Losada, Luis León-Mateos, Jorge García-González, Álvaro Pinto-Marín, Ignacio Duran, Rafael López-López, Urbano Anido-Herranz, Juan Ruiz-Bañobre

  • November 28, 2025

Related Content

MRI perfusion in evaluating ovarian masses: diagnostic performance of wash out rate

Recurrent pleuropulmonary blastoma type III initially misclassified as embryonal rhabdomyosarcoma on limited biopsy: a case report with pathogenic DICER1 variant

Case Report: Acute myeloid leukemia with mixed immunophenotypic features and TCF3::ZNF384 fusion in a pediatric patient with CNS involvement: a diagnostic and therapeutic challenge